Not available
Quote | Johnson & Johnson (NYSE:JNJ)
Last: | $146.03 |
---|---|
Change Percent: | 0.01% |
Open: | $146.43 |
Close: | $146.03 |
High: | $147.15 |
Low: | $145.74 |
Volume: | 4,901,741 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Johnson & Johnson (NYSE:JNJ)
2024-07-02 12:28:08 ET Summary iShares S&P 500 Value ETF weighs S&P 500 stocks based on their value characteristics. The IVE ETF is quite heavy in financials, but more balanced across sectors and holdings than its parent index. IVE has lagged the benchmark since incept...
2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...
Message Board Posts | Johnson & Johnson (NYSE:JNJ)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $JNJ taps 166. MH167.23 a BO186 HH | znewcar1 | investorshangout | 04/14/2023 7:58:15 PM |
Holding Big Pharma ACCOUNTABLE: J & J To | Agoura Guy | investorshub | 04/12/2023 1:41:45 AM |
whytestocks: $JNJ News Article - Why Johnson & Johnson Stock Was Climbing Today | whytestocks | investorshangout | 04/05/2023 7:50:45 PM |
whytestocks: $JNJ News Article - Traders Weigh Signs of Weakening Job Market, Shares Fall | whytestocks | investorshangout | 04/05/2023 3:35:47 PM |
whytestocks: $JNJ News Article - Better Dividend Stock: AbbVie vs. Johnson & Johnson | whytestocks | investorshangout | 04/05/2023 2:30:45 PM |
News, Short Squeeze, Breakout and More Instantly...
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study PR Newswire CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S....
2024-07-01 06:50:00 ET Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments. Three Motley Fool contributors think they've found magnificent stocks retir...
2024-06-29 08:21:00 ET We have closed the books on a strong first half of the year for the U.S. stock market, something that a lot of people overlooked. Now we embark on the second half of the year, which could bring some challenges, though July historically is the market's best-performing ...